Penicillin-resistant Neisseria meningitidis bacteraemia, Kimberley region, March 2010
DOI:
https://doi.org/10.33321/cdi.2010.34.36Keywords:
Neisseria meningitidis, penicillin resistant, meningococcus, meningococcal diseaseAbstract
A 4-year-old fully immunised male presented to a regional hospital in the West Kimberley with fever and lethargy. Blood cultures yielded serogroup B Neisseria meningitidis, resistant to benzylpenicillin (minimum inhibitory concentration (MIC) 1.0 mg/L). The patient was treated with intravenous ceftriaxone and made a complete recovery. Although invasive N. meningitidis isolates with reduced penicillin susceptibility are not uncommon in Australia, this is the first report of a benzylpenicillin-resistant isolate (MIC > 0.5 mg/L) causing invasive disease. As benzylpenicillin is currently recommended as first line empiric and definitive therapy for invasive meningococcal disease, the emergence of penicillin-resistant N. meningitidis disease is of concern and emphasises the importance of ongoing surveillance for antimicrobial resistance. Commun Dis Intell 2010;34(3):324–326.
Downloads
References
Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twentieth Informational Supplement (CLSI) M100-S20. 2010;30(1):101.
Jelfs J, Munro R, Wedege E, Caugant DA. Sequence variation in the porA gene for a clone of Neisseria meningitidis during epidemic spread. Clin Diagn Lab Immunol 2000;7(3):390–395.
Pereira L, Harnett G, Chidlow G, Speers D. Prevalence of genosubtypes (porA types) of invasive meningococcal disease in Western Australia from 2000 to 2006. Pathology 2008;40(7):728–729.
Janda WM, Gaydos CA. Neisseria. In: Murray PR, Baron EJ, JH Hoergensen JH, Landry ML, Pfaller MA, eds. Manual of Clinical Microbiology. Washington: ASM press; 2007 pp. 601–620.
Australian Meningococcal Surveillance Programme. Annual report of the Australian Meningococcal Surveillance Programme, 2008. Commun Dis Intell 2009;33(3):259–267.
Plessis M, Gottberg A, Cohen C, Gouveia L, Klugman K. Neisseia meningitidis intermediately resistant to penicillin and causing invasive disease in South Africa in 2001–2005. J Clin Microbiol 2008;46(10):3208–3214.
Hedberg ST, Fredlund H, Nicholas P, Caugant DA, Olcen P, Unemo M. Antibiotic susceptibility and characteristics of Neisseria meningitidis isolates from the African meningitis belt, 2000 to 2006: phenotypic and genotypic perspectives. Antimicrob Agents Chemother 2009;53(4):1561–1566.
Brown EM, Fisman DN, Drews SJ, Dolman S, Rawte P, Brown S, et al. Epidemiology of invasive meningococcal disease with decreased susceptibility to penicillin in Ontario, Canada 2000 to 2006. Antimicrob Agents Chemother 2010;54(3):1016–1021.
Antibiotic Writing Group. Central nervous system infections. Therapeutic guidelines – Antibiotic. 2006; version 13: pp 55–68.
Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Sceld WM, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004;39(9):1267–1284.
Apicella MA. Neisseria meningitidis. In: Mandell GL, Bennett JE, Dolin R eds. Mandell, Douglas and Bennett's. Principles and Practice of Infectious Disease. Elsevier Churchill Livingstone 2010; pp. 2737–2752.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2010 Communicable Diseases Intelligence

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
